{
    "paper_id": "c2ece2784753e05b88c63fb2fa09edd60d354650",
    "metadata": {
        "title": "Supplementary webappendix",
        "authors": []
    },
    "abstract": [],
    "body_text": [
        {
            "text": "*Only individuals with recorded age information **Proportion of cases in age category vs. proportion of cases in whole group",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supplementary"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Geographic distribution of MERS-CoV antibody-positive individuals No. MERS-CoV positive/tested (%) 994",
            "authors": [],
            "year": null,
            "venue": "Supplementary Table S5",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "*KSA population census (year 2013) was retrieved from the Saudi Arabia Central Department of Statistics & Information",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Detailed information on 22 stage 2 MERS-CoV antibody positive human serum samples Serum no. 20 was positive by rELISA and had an indecisive outcome in rIFA. As the serum was rated positive by PRNT 50 the final rating was stage 1 and stage 2 positive. SupplementaryTable S4. Correlation of serological status with age Group Age categories Total samples N* Confirmed MERS-CoV infections Chi 2 test**",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}